Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia There has been a resurgence of interest in the class I C antiarrhythmic agent flecainide fuelled by recent work identifying the drug as an effective treatment for catecholaminergic polymorphic ventricular tachycardia (CPVT). 1 -3 CPVT is caused by mutations in the sarcoplasmic reticulum (SR) Ca 2+ release channel (RyR2), or the associated proteins calsequestrin-2 or triadin, which lead to an increased propensity for spontaneous SR Ca 2+ waves during exercise or stress. These in turn induce a transient inward current due to Ca 2+ extrusion via the Na/Ca exchanger (NCX), delayed afterdepolarizations (DADs) and triggered action potentials. While it is increasingly accepted that flecainide is an effective treatment for CPVT, a degree of controversy has emerged regarding its mechanism of action.
Watanabe et al. provided the first evidence that, in addition to known inhibitory effects on the Na + current (I Na ), flecainide also acts directly on RyR2 to prevent pro-arrhythmic SR release, thereby providing a dual mode of action. 1 Subsequent work demonstrated that flecainide only inhibits RyR2 gating when the channel is in the open state. 4 The functional consequence of this effect on RyR2 is that the Ca 2+ flux associated with each diastolic Ca 2+ spark is reduced, while event frequency increases, such that there is no change in the SR Ca 2+ leak, SR Ca 2+ content, or systolic Ca 2+ release. On the basis of these findings, we proposed a new, primary antiarrhythmic mechanism, whereby the flecainide-induced decrease in the spark mass reduces the probability that Ca 2+ sparks will undergo salutatory propagation between junctional Ca 2+ release sites, which is the basis of pro-arrhythmic Ca 2+ waves. 4 The importance of flecainide's action on RyR2 was recently questioned by Priori and colleagues, who reported that flecainide did not inhibit Ca 2+ waves in a mouse model of CPVT. 5 Instead, the antiarrhythmic effects of flecainide were attributed to inhibition of I Na and a decrease in the probably of DADs triggering action potentials. However, as considered previously, 6 diastolic spark frequency was sufficiently high in this study to suggest that the cells were very Ca 2+ overloaded. Under Ca 2+ -overload conditions, we also find that flecainide is much less able prevent Ca 2+ waves and effects mediated via I Na inhibition would then dominate. 7 In this volume, a study by Sikkel et al. 8 also aims at addressing the mechanism by which flecainide influences Ca 2+ sparks and waves. In contrast to the findings by the Priori group 5 and consistent with our findings, 4 the authors report a decrease in Ca 2+ wave frequency in normal rat ventricular myocytes after exposure to flecainide. However, as other I Na blockers were equally effective in reducing Ca 2+ waves, the authors conclude that RyR2 inhibition is not relevant, and propose a mechanism whereby inhibition of I Na is linked to indirect effects on Ca 2+ Previous studies in intact myocytes from CPVT mice and isolated perfused rabbit hearts have shown that class I C agents that also inhibit RyR2 (flecainide and R-propafenone) are significantly more effective at blocking Ca 2+ waves and associated arrhythmias than drugs that only inhibit I Na (e.g. lidocaine and procainamide). 12, 13 Why then did Sikkel et al. not observe a more potent suppression of Ca 2+ waves by flecainide compared with other I Na inhibitors that lack RyR2 channel function (i.e. tetrodotoxin, lidocaine)? One important difference is that unlike Sikkel et al., Hwang et al., 7 and Lee et al. 12 kept the pacing rate constant and used beta-adrenergic stimulation with isoproterenol to induce Ca 2+ waves, experimental conditions that reduce the influence of Na + channel block on cellular Ca 2+ loading. Furthermore, Sikkel et al. applied 5 mM flecainide only for 5 min in the experiments comparing different Na + channel blockers in the voltage clamp studies at 240 mV, the only experiment designed to test the contribution of RyR2 block on Ca 2+ sparks and waves. However, as considered previously, flecainide enters myocytes slowly, 1, 14 and it takes up to 30 min to reach maximal effects on Ca 2+ waves in intact myocytes. 15 Hence, in all previous studies evaluating the role of RyR2 modulation, intact cells were exposed to 6 mM flecainide between 15 and 30 min before the assessment of Ca 2+ wave properties. 1, 4, 7 Sikkel et al. argue that 30 min exposure had no more effects on Ca 2+ wave frequency than 5 min exposure (Supplementary material online, Figure  SIII) . But those experiments were done in the same myocytes, and did not control for time dependent changes in wave frequency. In contrast to the results by Sikkel et al., we do not find any effect of flecainide on Ca 2+ waves after 5 min flecainide exposure, 15 indicating that experimental conditions of rapid pacing induced Ca 2+ waves are not comparable with our studies.
In permeabilized myocytes, the effect of flecainide on Ca 2+ sparks is rapid, consistent with the removal of the sarcolemma as a barrier to diffusion. 4 Sikkel et al. argue that effects of flecainide on RyR2 in permeabilized rat myocytes require cytosolic concentrations that are above those normally found within the plasma (i.e. 25 mM). 8 However, in a relevant disease model of CPVT myocytes, we find a flecainide IC 50 for reducing Ca 2+ wave frequency of 7 mM in permeabilized myocytes, 11 and of 2 mM in intact myocytes after 30 min incubation. 13 reports have shown a marked accumulation of flecainide in the ventricular myocardium. 1, 16 Taken together, the experimental conditions (rapid pacing induced [Na] i loading and short incubation times) chosen by Sikkel et al. strongly favour the detection of effects of I Na inhibition on Ca 2+ waves and hence the suppression of DADs, a property of Na + channel blockers that had been observed several decades ago. 10 On the other hand, the experiments by Sikkel et al. were not designed to detect the contribution of RyR2 block by class I C agents to their antiarrhythmic effects on Ca 2+ wave triggered arrhythmia, a contribution which has been confirmed independently by three groups. 7, 12, 17 We would caution that the absence of evidence does not constitute evidence for the absence of the therapeutic role of RyR2 modulation by flecainide. Rather, the mechanism of Ca 2+ wave suppression by flecainide described by Sikkel et al. is in addition to Ca 2+ wave suppression due to flecainide's direct action on RyR2 channels reported by us and others, and the reduced probability of DADs triggered action potentials described by the Priori group. This triple mode of action likely explains flecainide's striking clinical efficacy in CPVT patients.
